======= KHDRBS1 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: KHDRBS1
  * **<color #00a2e8>Official Name</color>**: KH RNA binding domain containing, signal transduction associated 1
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=10657|10657]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q07666|Q07666]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=KHDRBS1&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20KHDRBS1|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/602489|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**: N/A
  * **<color #00a2e8>UniProt Summary</color>**:  Recruited and tyrosine phosphorylated by several receptor systems, for example the T-cell, leptin and insulin receptors. Once phosphorylated, functions as an adapter protein in signal transduction cascades by binding to SH2 and SH3 domain- containing proteins. Role in G2-M progression in the cell cycle. Represses CBP-dependent transcriptional activation apparently by competing with other nuclear factors for binding to CBP. Also acts as a putative regulator of mRNA stability and/or translation rates and mediates mRNA nuclear export. Positively regulates the association of constitutive transport element (CTE)-containing mRNA with large polyribosomes and translation initiation. According to some authors, is not involved in the nucleocytoplasmic export of unspliced (CTE)-containing RNA species according to (PubMed:22253824). RNA-binding protein that plays a role in the regulation of alternative splicing and influences mRNA splice site selection and exon inclusion. Binds to RNA containing 5'-[AU]UAA-3' as a bipartite motif spaced by more than 15 nucleotides. Binds poly(A). Can regulate CD44 alternative splicing in a Ras pathway-dependent manner (By similarity). In cooperation with HNRNPA1 modulates alternative splicing of BCL2L1 by promoting splicing toward isoform Bcl-X(S), and of SMN1 (PubMed:17371836, PubMed:20186123). Can regulate alternative splicing of NRXN1 and NRXN3 in the laminin G-like domain 6 containing the evolutionary conserved neurexin alternative spliced segment 4 (AS4) involved in neurexin selective targeting to postsynaptic partners. In a neuronal activity-dependent manner cooperates synergistically with KHDRBS2/SLIM-1 in regulation of NRXN1 exon skipping at AS4. The cooperation with KHDRBS2/SLIM-1 is antagonistic for regulation of NXRN3 alternative splicing at AS4 (By similarity). {ECO:0000250|UniProtKB:Q60749, ECO:0000269|PubMed:15021911, ECO:0000269|PubMed:17371836, ECO:0000269|PubMed:20186123, ECO:0000269|PubMed:20610388, ECO:0000269|PubMed:22253824, ECO:0000269|PubMed:26758068}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|KH 1|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|Grb2-Sos complex|
|positive regulation of RNA export from nucleus|
|positive regulation of nucleobase-containing compound transport|
|regulation of RNA export from nucleus|
|regulation of nucleobase-containing compound transport|
|poly(A) binding|
|poly(U) RNA binding|
|positive regulation of translational initiation|
|SH3/SH2 adaptor activity|
|positive regulation of nucleocytoplasmic transport|
|regulation of alternative mRNA splicing, via spliceosome|
|regulation of translational initiation|
|regulation of mRNA splicing, via spliceosome|
|regulation of nucleocytoplasmic transport|
|G1/S transition of mitotic cell cycle|
|cell cycle G1/S phase transition|
|positive regulation of translation|
|G2/M transition of mitotic cell cycle|
|SH3 domain binding|
|cell cycle G2/M phase transition|
|regulation of RNA splicing|
|regulation of mRNA processing|
|positive regulation of cellular amide metabolic process|
|positive regulation of intracellular transport|
|protein domain specific binding|
|protein-containing complex binding|
|mitotic cell cycle phase transition|
|cell cycle phase transition|
|regulation of protein stability|
|regulation of mRNA metabolic process|
|regulation of intracellular transport|
|regulation of translation|
|regulation of cellular amide metabolic process|
|mRNA processing|
|protein complex oligomerization|
|posttranscriptional regulation of gene expression|
|spermatogenesis|
|male gamete generation|
|mitotic cell cycle process|
|mitotic cell cycle|
|gamete generation|
|mRNA metabolic process|
|multicellular organismal reproductive process|
|sexual reproduction|
|multicellular organism reproduction|
|RNA processing|
|regulation of cellular localization|
|positive regulation of transport|
|multi-organism reproductive process|
|cell cycle process|
|identical protein binding|
|negative regulation of transcription, DNA-templated|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|negative regulation of RNA metabolic process|
|cell cycle|
|negative regulation of cellular macromolecule biosynthetic process|
|RNA binding|
|reproductive process|
|reproduction|
|negative regulation of nucleobase-containing compound metabolic process|
|DNA binding|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|negative regulation of biosynthetic process|
|protein-containing complex assembly|
|positive regulation of cellular protein metabolic process|
|positive regulation of signal transduction|
|RNA metabolic process|
|positive regulation of protein metabolic process|
|negative regulation of gene expression|
|positive regulation of cell communication|
|positive regulation of signaling|
|protein-containing complex subunit organization|
|regulation of transport|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|membrane|
|gene expression|
|positive regulation of biosynthetic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp18|Doxycycline 10μM R00 exp18]]|-2.48|
|[[:results:exp530|Thioridazine 5μM R08 exp530]]|-2.24|
|[[:results:exp501|Methotrexate 0.01μM R08 exp501]]|-2.16|
|[[:results:exp209|Deguelin 0.15μM R05 exp209]]|-2.12|
|[[:results:exp27|Pimelic-diphenylamide-106 0.5μM R00 exp27]]|-2.09|
|[[:results:exp421|VHL-ligand-1 20μM R07 exp421]]|-2.02|
|[[:results:exp102|Nifuroxazide 5μM R03 exp102]]|-2.01|
|[[:results:exp399|Salubrinal 20μM R07 exp399]]|-1.98|
|[[:results:exp11|CCCP 1μM R00 exp11]]|-1.87|
|[[:results:exp30|Rapamycin 10μM R00 exp30]]|-1.86|
|[[:results:exp316|Geldanamycin 0.015 to 0.025μM on day4 R07 exp316]]|-1.74|
|[[:results:exp228|Demecolcine 0.03μM R05 exp228]]|1.7|
|[[:results:exp96|BI-2536 0.02μM R03 exp96]]|1.77|
|[[:results:exp487|Hinokiflavone 12μM R08 exp487]]|2.26|
|[[:results:exp75|MK-1775 0.32μM R02 exp75]]|2.29|
|[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|2.31|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|2.33|
|[[:results:exp350|Deferoxamine 11μM R07 exp350]]|2.33|
|[[:results:exp299|Talazoparib 0.006μM R06 exp299]]|2.63|
|[[:results:exp59|UMK57 1μM R01 exp59]]|2.88|
|[[:results:exp106|UM131593 0.2μM R03 exp106]]|2.96|
|[[:results:exp460|BML-284 0.09μM R08 exp460]]|3.58|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|6.28|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|6.5|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:u:ube3a|UBE3A]]|0.58|
|[[:human genes:a:actb|ACTB]]|0.514|
|[[:human genes:c:casp3|CASP3]]|0.511|
|[[:human genes:m:med13l|MED13L]]|0.475|
|[[:human genes:c:casp8|CASP8]]|0.46|
|[[:human genes:s:sp3|SP3]]|0.45|
|[[:human genes:f:fadd|FADD]]|0.442|
|[[:human genes:c:clk3|CLK3]]|0.44|
|[[:human genes:c:ccnc|CCNC]]|0.432|
|[[:human genes:z:znf592|ZNF592]]|0.431|
|[[:human genes:f:fbxo11|FBXO11]]|0.419|
|[[:human genes:t:tnfrsf10b|TNFRSF10B]]|0.406|
|[[:human genes:f:fnip1|FNIP1]]|0.406|
|[[:human genes:t:tceb3|TCEB3]]|0.404|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 1/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|1/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 5872
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 8.14 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='KHDRBS1 Expression in NALM6 Cells: 8.14'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>